OBJECTIVE: To provide physicians and the general public with a responsible assessment of current screening, prevention, and treatment approaches to @entity5 . @entity1 : The @entity1 were a non-Federal, nonadvocate, 13-member panel representing the fields of obstetrics and gynecology, gynecologic oncology, radiation oncology, and epidemiology. In addition, 28 experts in obstetrics and gynecology, gynecologic oncology, radiation oncology, gynecologic surgery, and psychology presented data to the panel and a conference audience of 500. EVIDENCE: The literature was searched through Medline and an extensive bibliography of references was provided to the panel and the conference audience. Experts prepared abstracts with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience. CONSENSUS PROCESS: The panel, answering predefined questions, developed their conclusions based on the scientific evidence presented in open forum and the scientific literature. The panel composed a draft statement that was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. CONCLUSIONS: @entity189 is causally related to infection with the @entity1082 ). Reducing the rate of @entity1083 by changes in sexual behaviors in young @entity1 and/or through the development of an effective HPV vaccine would reduce the incidence of this disease. Pap smear screening remains the best available method of reducing the incidence and mortality of @entity3 . @entity1 with stage @entity9216 disease have a high cure rate with either simple hysterectomy or, where fertility preservation is an issue, by cone biopsy with clear margins. For @entity1 with stage I and stage IIA disease, radical surgery and radiation are equally effective treatments. These @entity1 should be carefully selected to receive one treatment or the other, but not both, as their combined use substantially increases the cost and morbidity of treatment. @entity1 with more advanced, nonmetastatic disease should be treated with radiation. Recurrent @entity5 confined to the pelvis should be treated with the modality not previously received. Radiation is recommended to palliate symptoms in @entity1 with @entity3 .

National Institutes of Health Consensus Development Conference statement on XXXX . April 1-3, 1996.

@entity1 :: ('9606', 'Species') :: ['participants', 'Persons', 'patients', 'Women', 'PARTICIPANTS', 'people'] @entity9216 :: ('3642', 'Gene') :: ['IA1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer'] @entity1083 :: ('MESH:D030361', 'Disease') :: ['HPV infection'] @entity189 :: ('MESH:D002277', 'Disease') :: ['Carcinoma of the cervix'] @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease', 'invasive cervical cancer']
@entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']
